Rajavelu Esther — SEC insider filings
SEC reporting owner CIK 1903716. 12 insider filings on record with FilingPulse; latest filed 2026-11-10.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2022-01-10 to 2026-11-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 7 filings — 274,005 shares, $518,480 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
- Largest priced transaction: sale of 50,816 shares @ $2.36 ($119,926) in Spero Therapeutics, Inc., filed 2026-02-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | See Remarks, Director | 10 | — | 9 legs · 274,005 sh · $518,480 | 7 |
| Fulcrum Therapeutics, Inc. (FULC) | Chief Financial Officer | 2 | — | — | 2 |
Insider filings — Rajavelu Esther
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | Spero Therapeutics, Inc. (SPRO) | Sale (S): 40,851 @ $1.04 | EDGAR |
| 2026-05-06 | 4 | Spero Therapeutics, Inc. (SPRO) | Sale (S): 25,240 @ $2.51 | EDGAR |
| 2026-02-09 | 4 | Spero Therapeutics, Inc. (SPRO) | Sale (S): 37,101 @ $2.36 · Sale (S): 50,816 @ $2.36 | EDGAR |
| 2026-02-04 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 249,000 @ $0 · Sale (S): 18,442 @ $2.20 · Grant/award (A): 498,000 (derivative) @ $0 | EDGAR |
| 2025-11-12 | 4 | Spero Therapeutics, Inc. (SPRO) | Sale (S): 40,270 @ $2.37 | EDGAR |
| 2025-05-06 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 185,000 @ $0 | EDGAR |
| 2025-02-05 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 266,139 @ $0 · Grant/award (A): 100,000 @ $0 · Sale (S): 20,689 @ $0.78 | EDGAR |
| 2024-11-12 | 4 | Spero Therapeutics, Inc. (SPRO) | Sale (S): 23,351 @ $1.31 · Sale (S): 17,245 @ $1.30 | EDGAR |
| 2024-02-05 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 119,866 @ $0 | EDGAR |
| 2023-11-15 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 300,000 @ $0 | EDGAR |
| 2023-02-13 | 4 | Fulcrum Therapeutics, Inc. (FULC) | Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2022-01-10 | 4 | Fulcrum Therapeutics, Inc. (FULC) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1903716 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs